Formulation and Drug Delivery

Single-Use Membrane Filters Offer Fast Flow Rates

December 11, 2015

Millipore Express PHF hydrophilic, sterilizing-grade filters from EMD Millipore offer faster flow rates to speed the process or reduce the process footprint.

Nanotech Drug Delivery Research for Melanoma Treatment

December 11, 2015

Researchers from Oregon State University develop a new three-drug delivery system for cancer treatment.

PSL Completes Advanced Process Installations for Pharmaceutical Manufacturing in Singapore

December 10, 2015

PSL has installed several advanced contained filtration and drying facilities as part of an expansion of a pharmaceutical manufacturing plant in Singapore.

Assembly Biosciences Reports Successful Clinical Study on Gemicel

December 09, 2015

Assembly Biosciences reported a successful clinical study validating the use of the Gemicel technology platform for the oral delivery of biologic medications.

EMA Accepts Sandoz’s Biosimilar for Etanercept

December 08, 2015

Sandoz announces that the European Medicines Agency has accepted a MAA for a biosimilar of etanercept.

Seqirus Opens Corporate Headquarters in the United Kingdom

December 03, 2015

Seqirus, CSL Limited’s influenza vaccine business, announced the opening of their corporate headquarters in the United Kingdom.

Determining Biosimilarity

December 02, 2015

Analytical methods and functional assays are used to compare molecules and relate characteristics to quality attributes.

Fixed-Dose Combinations

December 02, 2015

The advantages of fixed-dose combinations are well recognized but their formulation and manufacture can be a challenge, Stefania Barzanti from IMA Active explains why.

GMP Challenges for Advanced Therapy Medicinal Products

December 02, 2015

Finalizing GMP requirements and quality standards for the development, manufacture, and clinical testing of ATMPs in the EU is proving to be a complex task.

Litigation and Manufacturing Hurdles Block US Biosimilars Market Success

December 02, 2015

The CEO of a US-based biosimilar manufacturer explains the legal and intellectual property issues of bringing a biosimilar to market in the United States.